Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Terminated 2Unknown 1

Sponsor Class

OTHER 6INDUSTRY 2NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 147Gastrointestinal 12CNS 6Tumor-Agnostic 4Genitourinary 4Thoracic 3Other hematologic neoplasm 3Lymphoid 3Sarcoma 2Plasma cell 2Head & Neck 2Gynecologic 2Endocrine 2Other solid neoplasm 1NET 1Myeloid 1Dermatologic 1Classical hematology 1

Conditions

Brain Neoplasms 3Neuroendocrine Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1HER2-positive Metastatic Breast Cancer 1Carcinoid Tumor 1Breast Neoplasms 1Adrenal Gland Neoplasms 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × pertuzumab × CNS × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT05323955 2026-03-17

BRIDGET

Duke University

Phase 2 Active not recruiting
48 enrolled
CNS

Brain Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
120 enrolled
CNS

Brain Neoplasms

NCT02598427 2018-02-28

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Duke University

Phase 1 Terminated
1 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡